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Abstract
Background: Urea cycle disorders (UCDs) are a group of rare inherited metabolic disorders. Affected individuals
often present with hyperammonemic encephalopathy (HE) and have an increased risk of severe neurologic disease
and early death. The study aims to provide epidemiologic data and to describe the disease manifestation and
short-term outcome.
Method: Cross-border surveillance of newly diagnosed patients with UCDs - below 16 years of age - was performed
from July 2012 to June 2015 in Germany and Austria and from January 2012 to December 2015 in Switzerland.
Inquiries were sent monthly to all Pediatric Departments in Germany and Switzerland, and quarterly to the Austrian
Metabolic Group. In addition, data were collected via a second source (metabolic laboratories) in all three countries.
Results: Between July 2012 and June 2015, fifty patients (Germany: 39, Austria: 7, Switzerland: 4) with newly diagnosed
UCDs were reported and later confirmed resulting in an estimated cumulative incidence of 1 in 51,946 live births. At
diagnosis, thirty-nine patients were symptomatic and 11 asymptomatic [10 identified by newborn screening (NBS), 1 by
high-risk-family screening (HRF)]. The majority of symptomatic patients (30 of 39 patients) developed HE with (n = 25) or
without coma (n = 5), 28 of them with neonatal onset. Despite emergency treatment 15 of 30 patients with HE already
died during the newborn period. Noteworthy, 10 of 11 patients diagnosed by NBS or HRF remained asymptomatic.
Comparison with the European registry and network for intoxication type metabolic diseases (E-IMD) demonstrated that
cross-national surveillance identified a higher number of clinically severe UCD patients characterized by earlier onset of
symptoms, higher peak ammonium concentrations in plasma and higher mortality.
Conclusion: Cross-border surveillance is a powerful tool to identify patients with UCDs demonstrating that (1) the
cumulative incidence of UCDs is lower than originally suggested, (2) the mortality rate is still high in patients with
neonatal onset of symptoms, and (3) onset type and peak plasma ammonium concentration predict mortality.
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Background
Urea cycle disorders (UCDs) are caused by inherited defi-
ciencies of six enzymes and two transporters that are
involved in irreversible detoxification of ammonium to
urea. They include deficiencies of N-acetylglutamate syn-
thase (NAGS-D; OMIM #237310), carbamylphosphate
synthetase 1 (CPS1-D; OMIM #237300), ornithine trans-
carbamylase (OTC-D; OMIM #311250), argininosuccinate
synthetase (ASS-D; OMIM #215700), argininosuccinate
lyase (ASL-D; OMIM #207900), arginase 1 (ARG1-D;
OMIM #207800), citrin or aspartate/glutamate carrier (cit-
rin-D, OMIM #603471 and #605814) and the mitochon-
drial ornithine transporter 1 causing hyperornithinemia-
hyperammonemia-homocitrullinuria syndrome (HHH
syndrome; OMIM #238970) [1]. Recently, inherited defi-
ciency of carbonic anhydrase VA (OMIM #615751) has
been identified as an additional, novel molecular cause of
hyperammonemic encephalopathy (HE) in infancy and
early childhood showing biochemical overlap with NAGS-
D and CPS1-D but also with carboxylases-dependent
metabolic disorders [2]. Except for OTC-D, which has an
X-linked inheritance, all UCDs are autosomal recessive.
UCD patients often present with early onset of symptoms
(EO, onset in the first 28 days) during the newborn period,
but can present with first symptoms at any age afterwards
(late onset, LO). Onset type is correlated with clinical se-
verity and outcome [3–5]. The most severe manifestation
is neonatal HE with coma (HE + C); it is associated with a
high risk of mortality and, in survivors, of severe neuro-
logic dysfunction and intellectual disability [6–8]. Note-
worthy, previous studies from the US and Japan showed
higher survival rates than those from Europe [9, 10]. Esti-
mated cumulative incidence of UCDs varies between
1:50,000 [11] and 1:8000 live births [12]. OTC-D, ASS-D
and ASL-D are the most common UCDs representing
about 90% [13]. Most likely the true incidence is higher
since some cases may remain undiagnosed: Patients with
EO are sometimes misdiagnosed as neonatal infections,
whereas UCD patients with LO may be missed due to
their variable phenotypic spectrum including hepatologi-
cal, gastrointestinal, neurological and psychiatric disease
manifestations [14–17]. Guidelines for diagnosis and man-
agement of UCDs have been published [1]. Maintenance
treatment of UCDs is based on a low protein diet, supple-
mentation with essential amino acids, citrulline and/or ar-
ginine, vitamins and minerals, and application of nitrogen
scavenger drugs (sodium benzoate, sodium and glycerol
phenylbutyrate) as well as carglumic acid (for NAGS-D
and partially responsive CPS1-D). During HE, treatment is
intensified stepwise by implementation of intravenous ni-
trogen scavenging therapy and extracorporeal detoxifica-
tion [1, 18, 19]. Liver transplantation is a curative therapy
for UCDs. Best outcome is achieved if liver transplantation
is carried out between age 3–12 months and before
irreversible brain damage manifests [1, 20, 21]. Hepato-
cyte transplantation is an experimental therapy which
can be used as a bridging procedure. Since transplanted
cells are short-lived, the need for liver transplantation
has not been averted by this approach [22–24]. One of
the major concerns is timely identification and undelayed
start of severity-adjusted therapy. For this purpose, some
UCDs – mostly ASS-D and ASL-D – have been included
in newborn screening (NBS) programmes in a few coun-
tries [13, 25]. Although preliminary results are promising
for LO patients, effectiveness remains to be demonstrated
for EO patients [5]. The study aims to provide epidemio-
logic data and to describe the severity of disease manifest-
ation, mortality and short-term outcome in UCD patients
in Germany, Austria and Switzerland.
Methods
Active surveillance of symptomatic individuals with urea
cycle disorders
Newly diagnosed individuals with UCDs - below 16 years
of age - were included in the cross-border nationwide
surveillance between 1st July 2012 and 30th June 2015.
In Germany, inquiries were sent monthly by German
Pediatric Surveillance Unit (ESPED) to all Departments
of Pediatrics (source A) and quarterly by University Hos-
pital Heidelberg to all specialized metabolic laboratories
(source B). In Austria, inquiries were sent quarterly by
one of the authors (DK) to the Austrian Metabolic
Group (source A) which includes pediatric metabolic
physicians, internists, clinical chemists, clinical geneti-
cists, and personnel from the Austrian NBS program
and specialized metabolic laboratories (source B). In
Switzerland, inquiries were sent monthly by Swiss Paedi-
atric Surveillance Unit (SPSU) to all pediatric hospitals
(source A) and quarterly by University Children’s Hos-
pital Zurich to all specialized metabolic laboratories
(source B). Newly diagnosed individuals with UCDs were
included into an MS Access database using a standard-
ized questionnaire with comprehensive information on
the diagnostic process, disease subtype, date of birth
(month and year), description of the first clinical presen-
tation, start and mode of specific metabolic treatment,
characteristic laboratory findings such as peak plasma
ammonium, plasma amino acids and urinary orotic acid,
and short-term clinical outcome. Information about ges-
tational age and complications in pregnancy were not
captured. The return rate of questionnaires was 100% in
Switzerland and Auatria, and 98% in Germany. Seven in-
dividuals were excluded from the study in Germany, four
with suspected but unconfirmed UCDs and three due to
disease manifestation before the start of the study. Three
Austrian UCD patients diagnosed outside the study
period or being older than 16 years of age were also ex-
cluded. In Switzerland, 6 patients were excluded due to
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criteria not met (n = 3), double reporting (n = 1), report-
ing of a known patient (n = 1), and yet unconfirmed
UCD with investigations ongoing (n = 1). False positive
and double reports were excluded from the analysis.
Comparison between this study and the E-IMD sample
Case mix, onset type, peak plasma ammonium concen-
trations and clinical symptoms during the initial clinical
manifestation, and mortality were compared between
this study and a previously published sample of 456
UCD patients [5].
Statistical analysis
Incidence of definite cases with UCDs were estimated
from the number of live births in Germany
(n = 2,102,583), Austria (n = 242,351) and Switzerland
(n = 252,380) during the study period. Cases reported
could be born before the start of the common study
period (1st July 2012) and could therefore belong to earl-
ier birth cohorts, whereas affected individuals born be-
tween 1st July 2012 to 30th June 2015 could have
remained asymptomatic during the surveillance period.
Furthermore, capture-recapture analysis was used as
previously described [26, 27]. This methodology was de-
signed to estimate population sizes on the basis of the
proportion of individuals (re)captured by two or more
sources. The Chapman estimate of the true number of
cases has been calculated as
N ¼ naþ 1ð Þ nbþ 1ð Þ
nabþ 1ð Þ −1
with na and nb denoting the number of individuals cap-
tured in data sources A and B, respectively, and nab repre-
senting individuals captured in both sources. Categorical
and count data were analyzed with log-linear models.
Mann-Whitney U-test was computed to detect differences
in central tendency for two groups. Differences in central
tendency between three or more groups were evaluated
with Aligned Rank Transform (ART) for nonparametric
factorial analyses. ART, a conventional analysis of variance
(ANOVA), was used for computation after the dependent
variable was “aligned” for each effect before ranked [28].
The R environment for statistical computing (2016) was
used for statistical and graphical computations, ARTool
package for R [28] was used to calculate ART ANOVA.
Post hoc contrasts were carried out with “least square
means” package for R [29]. Log-linear models were esti-
mated using vcd-package for R [30].
Results
Description of the study sample
Cross-border surveillance in Germany, Austria, and
Switzerland over three years (1st July 2012 to 30th June
2015) identified a total of 50 patients (Germany: 39 indi-
viduals, Austria: 7, Switzerland: 4) with newly diagnosed
UCDs (Table 1). All identified patients lived in Germany,
Austria or Switzerland. UCD patients from other coun-
tries were not included in this study. Tracking between
source A and B was possible in Germany, so capture-
recapture analysis was computed only for German cases.
In Germany, 35 patients were reported via source A, 25
via source B and 21 via both sources, all in all 39 pa-
tients. Since five individuals were exclusively reported by
metabolic laboratories, we did not receive clinical infor-
mation about these individuals. In Austria and
Switzerland, UCD patients were exclusively reported via
source A. Reported individuals with UCDs were born
between June 1998 and April 2015, 34 of them being
males and 16 females. The discrepancy in sex distribu-
tion was expected. It is explained by the high frequency
of OTC-D (n = 22 of 50 reported UCD patients) in the
study sample and the higher frequency of symptomatic
male (mOTC-D, n = 18) compared to female OTC-D
(fOTC-D, n = 4) patients due to X inheritance. All other
UCDs were less frequently found (CPS1-D: n = 8, ASS-
D: n = 10, ASL-D: n = 7, ARG1-D: n = 1, HHH syn-
drome: n = 1, citrin-D: n = 1). Individuals with NAGS-D
were not reported. Suspected diagnoses were confirmed
biochemically (n = 48) and/or by enzyme (n = 2) and/or
mutation analysis (n = 34). Twenty of the UCD patients
had family members with the same disease (18 patients
with one, and either one patient with two or four af-
fected family members). Thirteen family members had
OTC-D, six had ASS-D, four had CPS1-D, and one had
HHH syndrome. The majority of individuals with UCDs
were diagnosed after the manifestation of symptoms
(n = 39), whereas in some the diagnosis was made before
disease onset, either by NBS (n = 10) or by HRF (n = 1),
i.e. in a family with a previously identified index patient.
Patients identified by NBS were all from Germany. Al-
though the national German screening panel does not
include UCDs, pilot studies for UCDs are ongoing in
some NBS laboratories. Symptomatic UCD patients
Table 1 Reported individuals with urea cycle disorders
Country Source Reports (total) Reports (eligible)a
Germany A or B 58b 39
A 52 35
B 27 25
A and B 21 21
Austria A or B 10b 7
Switzerland A or B 11b 4
All countries A or B 79b 50
aExcluding false positive (unconfirmed diagnosis, onset of symptoms before
start of study, age at diagnosis above 16 years of age) and double reports
bNumber of patients reported via at least one source
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usually presented with first symptoms during the newborn
period (EO group: n = 28; median age at disease onset:
2 days, range: 1–7 days), whereas seven LO patients
presented at a median age of 1089 days (range: 303–
4018 days). Overall, diagnosis was made at a median age
of 3 days (range: 2–5844 days), however, with a marked
difference between the EO and LO groups [median age
(range) at diagnosis, EO: 3 (2–8) days; LO: 2178 (696–
5844) days] and between single UCDs (minimum: 2 days
in CPS1-D, maximum: 5844 days in fOTC-D). Further-
more, the diagnostic delay, i.e. the time interval between
the manifestation of first symptoms and diagnosis, mark-
edly differed between EO (median 1 day delay) and LO
(median: 1089 days delay) groups.
Clinical presentation and short-term outcome
A broad spectrum of clinical symptoms was found during
the initial presentation. These include HE (with or w/o
coma) in 30 patients, neurological (seizures/epilepsy: 16
patients, delayed motor development: n = 3, delayed cog-
nitive development: n = 3, movement disorders: n = 1, be-
havioral abnormalities: n = 4) and gastrointestinal
symptoms (recurrent vomiting: n = 8, protein aversion:
n = 4, failure to thrive: n = 1) as well as acute liver failure
(n = 5). Ten individuals with OTC-D (n = 1), ASS-D
(n = 4), ASL-D (n = 3), ARG1-D (n = 1), and citrin-D
(n = 1) were identified by NBS. One individual identified
by NBS developed symptoms on fifth day of life. Whereas
neurological symptoms were found across different UCDs,
acute liver failure was exclusively observed in patients
with mOTC-D (n = 3) and fOTC-D (n = 2), protein aver-
sion mostly in fOTC-D (n = 3), and recurrent vomiting
mostly in mOTC-D (n = 3) and fOTC-D (n = 3). Delayed
motor and cognitive development, movement disorder,
protein aversion, and failure to thrive were exclusively
found in the LO group, and behavioral abnormalities (EO:
1/28, LO: 3/7 patients), recurrent vomiting (EO: 4/28, LO:
4/7 patients) and acute liver failure (EO: 3/28, LO: 2/7 pa-
tients) were more frequent in the LO than in the EO
group. HE was reported in 30 individuals with UCDs, 25
of them being comatose (HE + C) on admission (Table 2).
It was most commonly found in the EO group (HE total:
27/28, HE + C: 24/27 patients) and less often in the LO
group (HE total: 3/7, HE + C: 1/3 patients). Highest fre-
quency and most severe HE was found in CPS1-D (HE
total: 7/8, HE + C: 6/7 patients) and mOTC-D (HE total:
15/17, HE + C: 13/15 patients).
Clinical severity was paralleled by peak plasma ammo-
nium concentrations: Highest peak plasma ammonium
concentrations were reported for CPS1-D and mOTC-D.
Initial ammonium concentrations were much higher in
the EO group than in the LO group and higher in the
HE + C group compared to HE without coma and
asymptomatic (AS) individuals (Table 3).
Table 2 Frequency of hyperammonemic encephalopathy (initial
presentation)
Disease name Patients
(n)
HE total
(n)
HE + C
(n)
CPS1-D 8 7 6
mOTC-D 17 15 13
fOTC-D 5 1 0
ASS-D 10 3 3
ASL-D 7 4 3
ARG1-D 1 0 0
HHH syndrome 1 0 0
Citrin-D 1 0 0
Total 50 30 25
HE hyperammonemic encephalopathy, HE + C HE with coma. In a single
patient with CPS1-D the manifestation of HE remained unknown
Table 3 Peak plasma ammonium concentration (before treatment)
Patients
(n)
Median (Range)
(μmol/L)
Disease name
CPS1-D 8 2333 (350–5400)
mOTC-D 17 1714 (110–8160)
fOTC-D 5 247 (73–498)
ASS-D 10 422 (40–1266)
ASL-D 7 320 (36–1471)
ARG1-D 1 63 (n/a)
HHH syndrome 1 60 (n/a)
Citrin-D 1 44 (n/a)
Total 50 935 (36–8160)
Onset typea
EO 28 1622 (199–8160)
LO 7 247 (60–498)
Asymptomatic 10 68 (36–110)
Unknowna 5 n/a
Initial hyperammonemia
HE 5 320 (150–1383)
HE + C 25 1945 (298–8160)
Peak plasma ammonia levels are different between EO and LO groups (U-test,
p < 0.0001) as well as between EO or LO and asymptomatic patients, respectively
(U-test, p < 0.001). Note that plasma ammonium concentrations are age-dependent:
Newborns (arterial cord blood), 50–159 μmol/L; infants and children, 24–48 μmol/l;
adults, 11–55 μmol/L (adapted from [38]). Peak plasma ammonia levels differed
between groups AS, HE and HE + C [ART ANOVA: F(2,37) = 36.63; p < 0.001].
Contrasts with Tukey p-value adjustment revealed significant differences between
all three groups: AS vs. HE (p = 0.024), AS vs. HE + C (p < 0.001) and HE vs. HE + C
(p = 0.005). EO, early onset; HE, hyperammonemic encephalopathy; HE + C, HE with
coma; LO, late onset; n/a, not applicable
aFive patients in whom clinical information was not available since they have
been exclusively reported by metabolic laboratories
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As a consequence of severe HE, the majority of pa-
tients from the EO group (21/28) required hemodialysis/
hemofiltration (20/21) or peritoneal dialysis (1/21),
whereas only one individual of the LO group required
extracorporeal detoxification (1/7 patients). Scavenger
therapy was applied to all individuals of the EO group
(28/28 patients) and to all except two patients from the
LO group (5/7 patients). Sodium benzoate was more fre-
quently administered (EO: 28/28, LO: 5/7 patients) than
sodium phenylbutyrate or sodium phenylacetate (EO:
14/28, LO: 3/7 patients). Probatory therapy with carglu-
mic acid was exclusively made in the EO group (13/28
patients). Despite emergency therapy 15 of 30 UCD pa-
tients (50%) with HE died during or shortly after the
clinical manifestation. Brain edema/herniation (n = 7)
and multi-organ failure (n = 5) were the most frequently
reported causes of death. The mortality rate was highest
in patients with mOTC-D (mortality rate: 10/17 pa-
tients = 59%) and CPS1-D (4/8 patients = 50%). All de-
ceased patients belonged to the EO group (mortality
rate: 15/28 EO patients = 54%) highlighting that the age
of disease onset, severity of clinical symptoms and
hyperammonemia predicted mortality. Noteworthy, nine
of ten individuals with UCDs who were identified by
NBS and one patient with HRF remained asymptomatic
until the end of the observation period.
Comparison between this study and the E-IMD sample
Cross-border national surveillance of UCDs in Germany,
Austria and Switzerland demonstrated a high frequency
of EO patients (28/35 = 80% of symptomatic patients
with known onset type), and a clear correlation between
the severity of the initial manifestation (HE, coma, peak
plasma ammonium concentration) and mortality. The
proportion of EO patients in our sample was much
higher than in the recently published European UCD
sample of the E-IMD patient registry (123/456 = 27% of
symptomatic patients) [5]. The design of both observa-
tional studies is different: (1) UCD patients in the E-
IMD registry are exclusively registered by specialized
metabolic centres, whereas the sample of the present
study is based on nationwide surveillances in Germany,
Austria and Switzerland; (2) the E-IMD registry includes
UCD patients of any age of diagnosis, whereas this study
only includes patients in whom diagnosis has been made
before age 16 years (in E-IMD, 379/456 = 83% patients
were diagnosed below age 16 years). To compare whether
differences between the E-IMD study and our study were
exclusively explained by differences in the study design or
by other factors, we first compared the case mix of both
samples (Table 4). Individuals with CPS1-D were more
frequent than expected and those with fOTC-D less fre-
quent than expected in this study compared to the E-IMD
sample (using Pearson residuals, p = 0.004). Next, we cal-
culated whether these differences were explained by the
age limit in this study (i.e. age of diagnosis below 16 years).
Omitting 77 UCD patients diagnosed after age 16 years
from the E-IMD sample did in fact eliminate the above
mentioned conditions for fOTC patients, however CPS1-
D patients still remained more frequent than expected in
this study. Furthermore, median age of diagnosis was
much lower [this study: 3 days, E-IMD with age of diagno-
sis below 16 years: 210 days (W = 12,395, p < 0.001, U-
test with continuity correction)], whereas median peak
plasma ammonium concentration [this study: 968 μmol/L,
E-IMD: 372 μmol/L; W = 4013, p = 0.0495, U-test with
continuity correction)] and mortality rate were higher
[this study: 15/49 = 31%, E-IMD: 12/379 = 3%; p < 0.001)]
in this study than in the E-IMD sample. This demon-
strates that the cut-off for age of diagnosis (i.e., 16 years)
used in this study can only explain the less frequent than
expected fOTC patients, but not the higher clinical sever-
ity and mortality of UCD patients in the present study.
Table 4 Case mix of this study and the E-IMD study
Disease name E-IMD study Patients (n, %) E-IMD study, age of diagnosis below 16 yearsa Patients (n, %) This study Patients (n, %)
NAGS-D 9 (2%) 7 (2%) 0
CPS1-D 21 (5%) 20 (5%) 8 (16%)
mOTC-D 109 (24%) 95 (25%) 17 (34%)
fOTC-D 146 (32%) 98 (26%) 5 (10%)
ASS-D 87 (19%) 82 (22%) 10 (20%)
ASL-D 61 (13%) 56 (15%) 7 (14%)
ARG1-D 12 (3%) 12 (3%) 1 (2%)
HHH syndrome 11 (2%) 9 (2%) 1 (2%)
Citrin-Db n/a n/a 1 (2%)
Total 456 (100%) 379 (100%) 50 (100%)
aUsing the same age cut-off as in the present study
bCitrin deficiency was excluded from the analysis since this disease is not included in the E-IMD study [5]
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Epidemiology
Cumulative estimated incidence of UCDs was calculated
based on the number of newly diagnosed UCD patients
(Germany: 39, Austria: 7, Switzerland: 4) and the num-
ber of live births in Germany (n = 2,102,583), Austria
(n = 242,351) and Switzerland (n = 252,380) during the
common study period from 1st July 2012 to 30th June
2015. Accordingly, estimated incidences were 1 in 53,912
(Germany; 95% CI 53,840–53,8985), 34,622 (Austria; 95%
CI 34,483–34,760) and 63,095 (Switzerland; 95% CI
62,849–63,341), with a cumulative estimated incidence of
1 in 51,946 (95% CI 51,883–52,009) live births for all
countries. Since affected individuals were reported via two
sources in Germany, we also estimated the incidence of
the German sample using the capture-recapture analysis.
This approach revealed a slightly higher incidence of 1 in
50,609 live births. The estimated overall cumulative inci-
dence is under-estimated due to exclusion of UCD pa-
tients diagnosed after the age of 16 years. Assuming a
similar proportion of UCD patients diagnosed after the
age of 16 years as in the E-IMD sample (i.e. 77/456 = 17%
of UCD patients) the estimated incidence would increase
to 1 in 38,406 live births in the three countries, still miss-
ing patients who remain un−/misdiagnosed.
Discussion
The major results of this cross-border study from
Germany, Austria and Switzerland are that (1) the esti-
mated cumulative incidence of UCD patients under
16 years of age is about 1 in 52,000 live births, (2) regis-
tries and observational studies focusing on the follow-up
of surviving patients are likely to underestimate the
number of UCD patients with a severe phenotype, (3)
despite increased awareness for UCDs, improved NICU
care, and evidence-based guidelines, the mortality rate of
EO patients is still high, in particular for CPS1-D and
mOTC-D, and (4) UCD patients identified by NBS had a
favourable short-term outcome.
Incidence
This study places the estimated incidence or UCDs
below 16 years of age at about 1 in 52,000 live births in
Germany, Austria and Switzerland ranging from about 1
in 63,000 (Switzerland) to 1 in 35,000 live births
(Austria). Assuming that the same cumulative incidence
is found in the 28 EU Member States, at least 100 new
UCD patients are to be expected each year (2015:
5,091,295 live births, http://www.ec.europa.eu/eurostat.
Similar estimated incidences have been reported in three
previous publications from the US (1 in 35,000 live
births; [13]), Japan (1 in 50,000 live births; [11]) and
Finland (1 in 39,000 live births; [31]). A previous report
from the US with a cumulative incidence of 1 in 8000
live births [12], however, is likely to over-estimate the
total incidence of UCD patients. Although our study
provides the first robust estimation of incidence for
UCDs in Germany, Austria and Switzerland, we assume
that the true incidence is under-estimated for the follow-
ing reasons: First, the number of UCD patients who have
not been reported or in whom the diagnosis has been
missed is unknown. Second, this study has excluded
UCD patients diagnosed after age 16 years, probably
around 20%. The risk of missing UCD patients is still a
relevant source of bias since patients with a fulminant
phenotype might die early and undiagnosed and later
manifestations can be unspecific. This notion is sup-
ported by the fact that 15 of 30 patients with HE in our
study died shortly after the manifestation of symptoms.
A recent meta-analysis evaluating 29 studies published
between 1978 and 2014 with 1542 participants in the
US, Japan and Europe confirms the overall high risk of
neonatal death in UCD patients with EO disease mani-
festation, except for ASL deficiency [7].
Clinical presentation and mortality
The clinical spectrum of initial presentations of UCD
patients in this study is broad including overwhelming
disease, neurological, gastrointestinal or hepatic symp-
toms. This is in line with previous studies from the US
and Europe [4, 17]. The broad range of differential diag-
noses with above mentioned clinical symptoms increases
the risk of missing the diagnosis. A limitation of this
study is the short observation period which may explain
why specific symptoms such as delayed motor and cog-
nitive development and movement disorder were exclu-
sively found in the LO group of patients.
Natural history, clinical outcome and survival of UCD
patients differ depending on residual enzyme activity,
gender (e.g. OTC-D), peak plasma ammonium concen-
trations, duration of hyperammonemia, and the age of
first symptoms [3–5, 7–9, 15, 17, 18]. Furthermore, clin-
ical outcome depends on local experience and clinical
skills of multiprofessional teams carrying for UCD pa-
tients [1]. Overall, EO patients, in particular mOTC-D,
showed the highest mortality and the poorest neuro-
logical outcome among those who survived. However,
more recent studies have identified an unexpectedly high
number of LO patients and of non-neurological disease
manifestations [14–16, 32, 33]. Furthermore, the case
mix of onset types differed in study samples worldwide
[7]. Whether this reflects true differences between popu-
lations or selection bias has remained unclear. The
present study speaks in favour of patient registries and
longitudinal observational studies particularly of UCD
patients with LO and a mild disease course. This is sup-
ported by the fact that a higher number of clinically se-
vere EO patients, higher peak plasma ammonium
concentrations and higher mortality were identified by
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the recent cross-border surveillance than in the E-IMD
patient registry. Furthermore, our study challenges the
recently published notion that survival in UCD patients
has improved over the last decades [10, 34]. In contrast,
our study demonstrates a continuing high mortality rate
of EO patients, in line with a recent meta-analysis [7],
and an observation study from Europe [8] We cannot
exclude, however, that the mentioned differences be-
tween these studies reflect current differences in diag-
nostic strategies, management and care between Europe,
Japan and the US.
Newborn screening programme for urea cycle disorders?
In Europe, UCDs are rarely – however, ASS-D and ASL-
D occasionally – included into national NBS pro-
grammes [25], but are commonly included in the US
[13]. The clinical benefit of this diagnostic intervention
for UCD patients is still unclear. However, a trend to-
wards improved neurological long-term outcome for
neonatally screened patients with ASS-D, ASL-D and
ARG1-D has been demonstrated recently [5]. Further-
more, NBS may identify individuals with benign pheno-
types such as untreated ASL-D individuals with normal
intellectual and psychomotor development without any
intervention [35–37]. Noteworthy, 10 of 11 UCD pa-
tients identified neonatally by NBS or HRF in this study
remained asymptomatic during the short observation
period highlighting a potentially positive effect of NBS
for UCD patients. However, since the design of this
study does not allow long-term follow-up and careful
evaluation of the natural history in this subgroup, these
studies still remain to be performed. Furthermore, it
should be considered that the time window to identify
newborns before the onset of first symptoms is often
narrow so that the impact of NBS on the outcome critic-
ally relies on the process quality of NBS programs such
as the time between taking the NBS samples and having
the NBS results. More systematic work and long-term
observational studies are required to elucidate whether
NBS programmes can reduce mortality and improve the
long-term neurological and intellectual outcome of UCD
patients. Most importantly, we also need improved
therapeutic approaches.
Conclusion
The cumulative incidence of UCDs in this study is in a
similar range as incidences recently reported for the US,
Japan and Finland [11, 13, 31] but significantly lower
than previously suggested [12]. This should be taken
into consideration for the design of future clinical trials
and care programmes. Despite increasing awareness,
beginning harmonization of management and care in
Europe according to a recently published guideline [1],
and improved emergency and NICU treatment, the
mortality rate of UCD patients with and EO disease
course is still very high in Germany, Austria and
Switzerland. This highlights that more efforts are re-
quired to identify affected individuals with UCDs as
early and as reliable as possible. Although new therapies
have been introduced over the years, improvement of
clinical outcome and mortality might simply reflect dis-
crepancies in the case mixes of the different study sam-
ples investigated.
Abbreviations
ANOVA: Analysis of variance; ARG1-D: Arginase 1 deficiency (synonym,
argininemia); ART: Aligned rank transform; AS: Asymptomatic; ASL-
D: argininosuccinate lyase deficiency; ASS-D: Argininosuccinate synthetase 1
deficiency (synonym, citrullinemia type 1); CI: Confidence interval; Citrin-
D: Citrin deficiency (synonym, citrullinemia type 2); CPS1-
D: Carbamylphosphate synthetase 1 deficiency; E-IMD: European registry and
network for Intoxication type Metabolic Diseases; EO: Early onset of
symptoms (i.e., during the newborn period); ESPED: German pediatric
surveillance unit; F: Female; HE: Hyperammonemic encephalopathy;
HE + C: Hyperammonemic encephalopathy with coma; HHH
syndrome: Hyperornithinemia-hyperammonemia-homocitrullinuria syndrome;
HRF: High-risk family screening (i.e. family with a previously identified index
patient); LO: Late onset of symptoms (i.e., after the newborn period);
M: Male; NAGS-D: N-acetylglutamate synthase deficiency; NBS: Newborn
screening; OTC-D: Ornithine transcarbamylase deficiency; SPSU: Swiss
paediatric surveillance unit; UCD(s): Urea cycle disorder(s)
Acknowledgements
We are indebted to all patients and their families who have been willing to
contribute to this study, to share their experience on living with a rare
disease, and for their trust.
Funding
The study was partially supported by grants from the Dietmar Hopp Foundation,
the Kindness for Kids Foundation, Munich, Germany, and the European Union for
the project E-IMD (EAHC no 2010 12 01), in the framework of the Health
Programme 2008–2013 – both to SK. The work on urea cycle disorders is
supported by the Swiss National Science Foundation (grant 310030_153196 to
JH). The authors confirm independence from the sponsors; the content of the
article has not been influenced by the sponsors.
Availability of data and materials
All data generated or analysed during this study are included in this published
article. The datasets analysed during the current study are available from the
corresponding author on reasonable request.
Authors’ contributions
All authors made substantial contributions and have given final approval to the
version being submitted. SK, SN, GFH, JH and SFG developed the study design
and coordinated the whole study. SN, SK and BH coordinated the data
collection in Germany, JH in Switzerland, and DK in Austria. SFG, FG and SK
were responsible for data base management, mathematical modeling and
statistical analysis. SK, SFG and RP wrote the manuscript to which all co-authors
contributed as well. All authors read and approved the final manuscript.
Competing interests
The authors declare that they have no competing interests. Dr. Kölker reports
grants from the European Union, the German Research Foundation, Kindness
for Kids Foundation, and Dietmar Hopp Foundation and has received
personal fees from Danone Company and Recordati Rare Diseases Fondation
d’entreprise during the conduct of the study. This funding is outside the
submitted work. Dr. Hoffmann has received additional funding outside the
submitted work from the Dietmar Hopp Foundation during the conduct of
the study. Dr. Häberle has not received any funds during conduct of the
study; he has consultancy agreements with Orphan Europe Recordati and
Swedish Orphan Biovitrum but this was not in relation to the present study.
Mrs. Nettesheim, Mrs. Heinrich, Mr. Gleich, Dr. Garbade and Dr. Posset have
Nettesheim et al. Orphanet Journal of Rare Diseases  (2017) 12:111 Page 7 of 8
not received any funding during the study or outside the submitted work.
Dr. Karall has no conflict of interest in the conduction of this study.
Consent for publication
Not applicable.
Ethics approval and consent to participate
All procedures followed were in accordance with the ethical standards of
the responsible committee on human studies (institutional and national) and
with the Helsinki Declaration of 1975, as revised in 2000. The study has been
approved by the local ethics committee in Heidelberg (S-414/2011),
Innsbruck (UN4459–304/4.8) and Zurich (KEK-StV-Nr. 33/11).
Author details
1Division of Neuropediatrics and Metabolic Medicine, Center for Child and
Adolescent Medicine, University Hospital Heidelberg, Im Neuenheimer Feld
430, 69120 Heidelberg, Germany. 2Medical University of Innsbruck, Clinic for
Pediatrics I, Inherited Metabolic Disorders, Innsbruck, Austria. 3University
Children’s Hospital Zurich, Division of Metabolism and Children’s Research
Center, Zurich, Switzerland. 4Erhebungseinheit für Seltene Pädiatrische
Erkrankungen in Deutschland, Coordination Center for Clinical Studies,
Heinrich Heine University Düsseldorf, Düsseldorf, Germany.
Received: 6 March 2017 Accepted: 30 May 2017
References
1. Haberle J, Boddaert N, Burlina A, Chakrapani A, Dixon M, Huemer M, et al.
Suggested guidelines for the diagnosis and management of urea cycle
disorders. Orphanet J Rare Dis. 2012;7:32.
2. van Karnebeek CD, Sly WS, Ross CJ, Salvarinova R, Yaplito-Lee J, Santra S, et
al. Mitochondrial carbonic anhydrase VA deficiency resulting from CA5A
alterations presents with hyperammonemia in early childhood. Am J Hum
Genet. 2014;94:453–61.
3. Bachmann C. Outcome and survival of 88 patients with urea cycle disorders:
a retrospective evaluation. Eur J Pediatr. 2003;162:410–6.
4. Kolker S, Garcia-Cazorla A, Valayannopoulos V, Lund AM, Burlina AB, Sykut-
Cegielska J, et al. The phenotypic spectrum of organic acidurias and urea cycle
disorders. Part 1: the initial presentation. J Inherit Metab Dis. 2015;38:1041–57.
5. Posset R, Garcia-Cazorla A, Valayannopoulos V, Teles EL, Dionisi-Vici C,
Brassier A, et al. Age at disease onset and peak ammonium level rather than
interventional variables predict the neurological outcome in urea cycle
disorders. J Inherit Metab Dis. 2016;39:661–72.
6. Brassier A, Gobin S, Arnoux JB, Valayannopoulos V, Habarou F, Kossorotoff
M, et al. Long-term outcomes in Ornithine Transcarbamylase deficiency: a
series of 90 patients. Orphanet J Rare Dis. 2015;10:58.
7. Burgard P, Kolker S, Haege G, Lindner M, Hoffmann GF. Neonatal mortality
and outcome at the end of the first year of life in early onset urea cycle
disorders–review and meta-analysis of observational studies published over
more than 35 years. J Inherit Metab Dis. 2016;39:219–29.
8. Unsinn C, Das A, Valayannopoulos V, Thimm E, Beblo S, Burlina A, et al.
Clinical course of 63 patients with neonatal onset urea cycle disorders in
the years 2001-2013. Orphanet J Rare Dis. 2016;11:116.
9. Ah Mew N, Krivitzky L, McCarter R, Batshaw M, Tuchman M, Urea Cycle
Disorders Consortium of the Rare Diseases Clinical Research N. Clinical
outcomes of neonatal onset proximal versus distal urea cycle disorders do
not differ. J Pediatr. 2013;162:324–9. e321
10. Kido J, Nakamura K, Mitsubuchi H, Ohura T, Takayanagi M, Matsuo M, et al.
Long-term outcome and intervention of urea cycle disorders in Japan.
J Inherit Metab Dis. 2012;35:777–85.
11. Nagata N, Matsuda I, Oyanagi K. Estimated frequency of urea cycle
enzymopathies in Japan. Am J Med Genet. 1991;39:228–9.
12. Brusilow SW, Maestri NE. Urea cycle disorders: diagnosis, pathophysiology,
and therapy. Adv Pediatr Infect Dis. 1996;43:127–70.
13. Summar ML, Koelker S, Freedenberg D, Le Mons C, Haberle J, Lee HS, Kirmse B,
European R, Network for Intoxication Type Metabolic Diseases. Electronic
address hwe-ioeip, Members of the Urea Cycle Disorders Consortium.
Electronic address hreueu: The incidence of urea cycle disorders. Mol Genet
Metab 2013, 110:179-180.
14. Kolker S, Valayannopoulos V, Burlina AB, Sykut-Cegielska J, Wijburg FA, Teles EL,
et al. The phenotypic spectrum of organic acidurias and urea cycle disorders.
Part 2: the evolving clinical phenotype. J Inherit Metab Dis. 2015;38:1059–74.
15. Nassogne MC, Heron B, Touati G, Rabier D, Saudubray JM. Urea cycle
defects: management and outcome. J Inherit Metab Dis. 2005;28:407–14.
16. Ruegger CM, Lindner M, Ballhausen D, Baumgartner MR, Beblo S, Das A, et
al. Cross-sectional observational study of 208 patients with non-classical
urea cycle disorders. J Inherit Metab Dis. 2014;37:21–30.
17. Summar ML, Dobbelaere D, Brusilow S, Lee B. Diagnosis, symptoms, frequency
and mortality of 260 patients with urea cycle disorders from a 21-year, multicentre
study of acute hyperammonaemic episodes. Acta Paediatr. 2008;97:1420–5.
18. Enns GM, Berry SA, Berry GT, Rhead WJ, Brusilow SW, Hamosh A. Survival
after treatment with phenylacetate and benzoate for urea-cycle disorders. N
Engl J Med. 2007;356:2282–92.
19. Husson MC, Schiff M, Fouilhoux A, Cano A, Dobbelaere D, Brassier A, et al.
Efficacy and safety of i.v. sodium benzoate in urea cycle disorders: a
multicentre retrospective study. Orphanet J Rare Dis. 2016;11:127.
20. McBride KL, Miller G, Carter S, Karpen S, Goss J, Lee B. Developmental
outcomes with early orthotopic liver transplantation for infants with
neonatal-onset urea cycle defects and a female patient with late-onset
ornithine transcarbamylase deficiency. Pediatrics. 2004;114:e523–6.
21. Morioka D, Kasahara M, Takada Y, Shirouzu Y, Taira K, Sakamoto S, et al.
Current role of liver transplantation for the treatment of urea cycle
disorders: a review of the worldwide English literature and 13 cases at
Kyoto University. Liver Transpl. 2005;11:1332–42.
22. Meyburg J, Das AM, Hoerster F, Lindner M, Kriegbaum H, Engelmann G, et al.
One liver for four children: first clinical series of liver cell transplantation for
severe neonatal urea cycle defects. Transplantation. 2009;87:636–41.
23. Meyburg J, Hoffmann GF. Liver, liver cell and stem cell transplantation for the
treatment of urea cycle defects. Mol Genet Metab. 2010;100(Suppl 1):S77–83.
24. Stephenne X, Najimi M, Sibille C, Nassogne MC, Smets F, Sokal EM. Sustained
engraftment and tissue enzyme activity after liver cell transplantation for
argininosuccinate lyase deficiency. Gastroenterology. 2006;130:1317–23.
25. Loeber JG, Burgard P, Cornel MC, Rigter T, Weinreich SS, Rupp K, et al.
Newborn screening programmes in Europe; arguments and efforts regarding
harmonization. Part 1. From blood spot to screening result. J Inherit Metab Dis.
2012;35:603–11.
26. Hook EB, Regal RR. Capture-recapture methods in epidemiology: methods
and limitations. Epidemiol Rev. 1995;17:243–64.
27. Klose DA, Kolker S, Heinrich B, Prietsch V, Mayatepek E, von Kries R, et al. Incidence
and short-term outcome of children with symptomatic presentation of organic
acid and fatty acid oxidation disorders in Germany. Pediatrics. 2002;110:1204–11.
28. Kay M, Wobbrock J: ARTool: Aligned rank transform for nonparametric
factorial ANOVAs. R package version 0.10.2. 2016.
29. Lenth RV. Least-squares means: the R Package lsmeans. J Stat Softw. 2016;69:33.
30. Zeileis A, Meyer D, Hornik K. Residual-based shadings for visualizing
(conditional) independence. J Comput Graph Stat. 2007;16:507–25.
31. Keskinen P, Siitonen A, Salo M. Hereditary urea cycle diseases in Finland.
Acta Paediatr. 2008;97:1412–9.
32. Gallagher RC, Lam C, Wong D, Cederbaum S, Sokol RJ. Significant hepatic
involvement in patients with ornithine transcarbamylase deficiency. J
Pediatr. 2014;164:720–5. e726
33. Tuchman M, Lee B, Lichter-Konecki U, Summar ML, Yudkoff M, Cederbaum
SD, et al. Cross-sectional multicenter study of patients with urea cycle
disorders in the United States. Mol Genet Metab. 2008;94:397–402.
34. Waisbren SE, Gropman AL, Members of the Urea Cycle Disorders C, Batshaw
ML. Improving long term outcomes in urea cycle disorders-report from the
Urea Cycle Disorders Consortium. J Inherit Metab Dis. 2016;39:573–84.
35. Widhalm K, Koch S, Scheibenreiter S, Knoll E, Colombo JP, Bachmann C, et
al. Long-term follow-up of 12 patients with the late-onset variant of
argininosuccinic acid lyase deficiency: no impairment of intellectual and
psychomotor development during therapy. Pediatrics. 1992;89:1182–4.
36. Ficicioglu C, Mandell R, Shih VE. Argininosuccinate lyase deficiency: longterm
outcome of 13 patients detected by newborn screening. Mol Genet Metab.
2009;98:273–7.
37. Mercimek-Mahmutoglu S, Moeslinger D, Haberle J, Engel K, Herle M, Strobl MW,
et al. Long-term outcome of patients with argininosuccinate lyase deficiency
diagnosed by newborn screening in Austria. Mol Genet Metab. 2010;100:24–8.
38. Colombo JP, Peheim E, Kretschmer R, Dauwalder H, Sidiropoulos D. Plasma
ammonia concentrations in newborns and children. Clin Chim Acta. 1984;
138:283–91.
Nettesheim et al. Orphanet Journal of Rare Diseases  (2017) 12:111 Page 8 of 8
